author-photo

Douglas Adkins

Washington University in St. Louis

296

Papers

7301

Citations

Citation Trend

Filter By

Papers (296) Sort By

Journal Conference Others

nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.

2021 Medical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
358 Ramucirumab in combination with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma: a phase 1–2 trial

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

2021 The Lancet Diabetes & Endocrinology
Show All
- Source
- Cite
- Save
Citations (10)
Abstract CT153: Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy to patients with human papillomavirus-unrelated, locally advanced head and neck squamous-cell carcinoma

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.

2021 Oral Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.

2021 Oral Oncology
Show All
- Source
- Cite
- Save
Citations (1)